|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sanofi-Aventis |
| Information provided by: | Sanofi-Aventis |
| ClinicalTrials.gov Identifier: | NCT00344942 |
Purpose
To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients pressenting with Chronic Non Allergic and Non Infectious Rhinitis
| Condition | Intervention | Phase |
|
Chronic Non Allergic and Non Infectious Rhinitis |
Drug: triamcinolone acetonide |
Phase III |
| ChemIDplus related topics: | Triamcinolone acetonide Triamcinolone Triamcinolone diacetate Triamcinolone hexacetonide |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomised, Double-Blind, French Multi-Centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults |
Eligibility
| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
More Information
| Study ID Numbers: | TRICA-L-00872, EudraCT #: 2006-000059-16 |
| First Received: | June 26, 2006 |
| Last Updated: | July 18, 2008 |
| ClinicalTrials.gov Identifier: | NCT00344942 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|